Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.69
(
-0.96%
)
Bitcoin
74,336.17
(
0.53%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 68068

Sunday, 05/03/2009 9:45:00 PM

Sunday, May 03, 2009 9:45:00 PM

Post# of 257253
AZN – The JUPITER trial is having a material effect on Crestor sales, evidently. Worldwide 1Q09 sales of Crestor were $969M, +35% year-over-year in local currencies.

Crestor’s TRx share in the US anti-cholesterol market rose to 10.3% in March 2009, and Crestor is the only statin that is gaining US market share.

Source: http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q1-2009/AZN-Q1-results-09-Narrative.pdf


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now